Paul Tudor Jones’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Paul Tudor Jones’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-110,706	Closed	-$916K	–	2081
2021 Q1	$916K	Buy	110,706 +47,944	+76%	+$506K	0.02%	880
2020 Q4	$428K	Buy	+62,762	New	+$504K	0.01%	1011
2020 Q3	–	Sell	-27,683	Closed	-$174K	–	1612
2020 Q2	$174K	Buy	+27,683	New	+$106K	0.01%	1043
2020 Q1	–	Sell	-12,120	Closed	-$41K	–	1406
2019 Q4	$41K	Buy	+12,120	New	+$28.9K	﹤0.01%	1096
2018 Q2	–	Sell	-108,872	Closed	-$561K	–	1283
2018 Q1	$561K	Buy	108,872 +77,912	+252%	+$554K	0.02%	521
2017 Q4	$118K	Buy	+30,960	New	+$80.6K	﹤0.01%	1018
2016 Q2	–	Sell	-35,500	Closed	-$191K	–	2007
2016 Q1	$191K	Sell	35,500 -9,209	-21%	-$53.5K	﹤0.01%	1517
2015 Q4	$389K	Buy	+44,709	New	+$377K	0.01%	1066

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Paul Tudor Jones's SRNE Position: Q2 2021 in Review

Paul Tudor Jones sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 110,706 shares — an estimated $916K sold.

Paul Tudor Jones first reported a position in SRNE in Q4 2015 and held it in 8 quarters. The position peaked at $916K in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

Paul Tudor Jones reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Paul Tudor Jones sold 110,706 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $916K.
Paul Tudor Jones first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 8 quarters.
Paul Tudor Jones's Sorrento Therapeutics, Inc. position peaked at $916K in Q1 2021.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Tudor Investment Corp's 13F filing for Q2 2021, filed 16 Aug 2021.